AURA (Aura Biosciences, Inc.) Forward P/E Multiple

Official company branding of Aura Biosciences (AURA)

The market dynamics of the asset help assess the path of Aura Biosciences, Inc. (AURA) toward creating targeted ocular oncology therapy, where the indicator stands at 0.00. The team led by E. Capucci relies on deep scientific expertise and a clear strategic direction. Current business momentum is supported by capital from new investors, as there are no stable profit generators and developments are completing the final stages of testing.

Aura Biosciences - AURA Forward P/E Multiple (period 07/04/2022 - 11/18/2026)

Summary analytical data breakdowns for Aura Biosciences, Inc. (AURA)

- current price and projected stock value:
Comprehensive company analysis:Aura Biosciences Inc AURA
Brand item of Aura Corp

Forward P/E determines the value of a single share relative to the projected earnings for the next 12 months. By analyzing the expected NTM P/E of Aura Biosciences, Inc. (AURA), an investor sees the current market valuation of future cash flows. The value 0.00 reflects the premium paid for every dollar of expected income. High metrics are acceptable for Aura Biosciences, Inc. (AURA) due to the exclusivity of VDC technology. The monopoly potential of this eye cancer therapy justifies a premium valuation of its fundamental value.

Analysis of competing companies

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Projected Price to Earnings Candel Therapeutics, Inc. CADL|Forward P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Future Price to Earnings|ACTU: Projected Price to Earnings|Citius Oncology, Inc. - Market Cap to Future Earnings Ratio|HURA (TuHURA Biosciences) - Projected Price to Earnings|TARA: Market Cap to Future Earnings Ratio|Projected Price to Earnings FATE|WHWK: Future Price to Earnings Multiple|Projected Price to Earnings TCRX (TScan Therapeutics Inc)|Market Cap to Projected Earnings Champions Oncology Inc|Forward P/E Multiple XBIT (XBiotech Inc.)|Future Price to Earnings Multiple CVM|OS Therapies Inc. - Forward P/E Multiple|RADX - Forward P/E Multiple|ARTV: Forward P/E Multiple|ANL: Market Cap to Future Earnings Ratio|Projected Price to Earnings VERU|TPST: Future Price to Earnings Multiple|Future Price to Earnings xiliotx.com (XLO)|Renovaro - Price to Future Earnings Ratio|Future Price to Earnings Mural Oncology MURA|KAPA - Projected Price to Earnings|OKUR - Future Price to Earnings|GDTC - Forward P/E Multiple|Curis, Inc. (CRIS) - Future Price to Earnings|Projected Price to Earnings Apollomics, Inc.|Projected Price to Earnings THAR|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple